Is adjuvant chemotherapy justified in rectal cancer patients after radiochemotherapy and radical resection? by Bujko, Krzysztof
157
Short review
NOWOTWORY Journal of Oncology 
2018, volume 68, number 3, 157–160
DOI: 10.5603/NJO.2018.0025
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Ist Department of Radiotherapy, Maria Skłodowska-Curie Institute — Oncology Centre, Warszawa, Poland
Is adjuvant chemotherapy justified in rectal cancer patients after radio-
chemotherapy and radical resection?
Krzysztof Bujko
Recommendations for the application of post-operative adjuvant chemotherapy in patients who received preope-
rative radio-chemotherapy are not consistent. Some of them advise post-operative chemotherapy, whilst others 
follow-up without any adjuvant treatment. The objective of this paper is to undertake an overview of the randomised 
studies evaluating whether the administration of adjuvant chemotherapy can be justified with clinical evidence. 
A systematic overview of the publications shows 5 randomised trials in which only the patients after pre-operative 
radio-chemotherapy were enrolled, whilst randomisation concerned adjuvant therapy vs follow-up without adjuvant 
therapy. None of the studies showed any improvement after post-operative chemotherapy with regards to both the 
overall survival and disease-free survival rate. Moreover, 3 randomised studies were found in which post-operative 
chemotherapy with fluoropyrimidine was compared with post-operative chemotherapy with fluoropyrimidine with 
the addition of oxaliplatin. One of these studies showed an improvement in the overall survival rate after the use 
of post-operative chemotherapy, whereas in two others the difference was statistically insignificant. Two studies 
showed a slight improvement after chemotherapy with regards to disease-free survival rates, whilst no such effect 
was observed in the third. A meta-analysis of the studies comparing the results after the administration of post-ope-
rative chemotherapy with the results after the chemotherapy-free follow-up did not demonstrate any positive effect 
of the chemotherapy on the overall and disease-free survival rate. A meta-analysis of randomised studies in which 
post-operative chemotherapy with fluoropyrimidine was compared with post-operative chemotherapy with fluoro-
pyrimidine with the addition of oxaliplatin did not show any improvement in disease-free survival rates in patients 
receiving oxaliplatin. The overall survival was not analysed because of the lack of appropriate data at the moment 
the meta-analysis was made. The above overview of the randomised trials points to a lack of any strong evidence 
justifying the administration of post-operative chemotherapy.
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Introduction
This paper deals solely with patients diagnosed with 
advanced rectal cancer who received pre-operative radio-
-chemotherapy. Recommendations concerning the admini-
stration of post-operative adjuvant chemotherapy in these 
patients are not consistent. The guidelines of the National 
Comprehensive Cancer Network recommend administra-
tion in the patients with clinical stage II–III of the disease, 
irrespectively of the tumour’s response to irradiation [1]. 
The guidelines of the Medical Society for Medical Oncology 
restrict the administration of adjuvant chemotherapy to 
patients with pathological stage III of the disease, and to 
the patients with stage II if the recurrence of risk is very high 
[2]. In contrast to the above guidelines, Dutch and Norwe-
gian recommendations do not advise the administration of 
chemotherapy [3]. The difference of opinion concerning the 
advisability of the administration of post-operative chemo-
therapy is also observed among European experts [4]. The 
differences are also seen in routine practice: for example 
a  Swedish population study showed that, depending on 
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the region, among the patients with stage III of the disease, 
the rate of those receiving adjuvant chemotherapy varied 
between 13% and 77% [5]. This paper is an overview of ran-
domisation studies with an objective to evaluate whether 
the administration of adjuvant chemotherapy is justified 
by clinical evidence. 
The overview of randomised trials comparing 
post-operative chemotherapy with observation 
A systematic overview of publications [6], revealed 5 ran-
domised trials which fulfilled the following criteria:
1. Only patients after pre-operative radio-chemotherapy 
were included,
2.  Patients were randomised for adjuvant chemotherapy 
or for a observation without adjuvant chemotherapy 
[7–13].
The total number of patients included in all these 5 stu-
dies was 2398. In 4 studies, 5-fu was administered [7–10, 
12, 13], whilst in the fifth — oxaliplatin was added to 5-fu 
[11]. None of these 5 studies saw any improvement after 
post-operative chemotherapy with regards either to overall 
survival and to disease-free survival. A detailed discussion 
of these studies is presented below. 
In the EORTC 22921 study (n [number of patients] = 1011) 
the patients were randomly allocated to 4 study arms, and 
randomisation was used twice — for pre-operative radio-che-
motherapy vs pre-operative radiotherapy and also post-ope-
rative chemotherapy vs follow-up [7, 8]. The 10-year overall 
survival rate was 51.8% in the patient group with post-opera-
tive chemotherapy and 48.4% in those patients undergoing a 
follow-up without post-operative chemotherapy, hazard ratio 
(HR) 0.91 (95% confidence interval [CI] 0.77–1.09), p = 0.32. 
The respective values for disease-free survival were 47.0% 
and 43,7%; HR = 0.91 (95% CI 0.77–1.08), p = 0.29. 
An Italian study (n = 643) showed a 5-year overall survi-
val rate of 66.9% in the patient group with post-operative 
chemotherapy and 67.9% in the control group, p = 0.88 [9]. 
The respective values for disease-free survival were 63.8% 
and 60.8%, p = 0.42.
In the PROCTOR/SCRIPT study (n = 437), a 5-year overall 
survival was observed in 79.2% of patients in the group 
receiving post-operative chemotherapy and 79.2% in the 
control group, HR = 0.93 (95% CI 0.62–1.39), p = 0.73 [10]. 
The respective values for disease-free survival were 62.7% 
and 55.4%, HR = 0.80 (95% CI 0.02–1.07), p = 0.13.
The CHRONICLE study was discontinued due to a poor 
accrual after the inclusion of merely 113 patients [11]. The 
median of the follow-up period was short — 3.6 years. 3-year 
overall survival amounted to 89% in patients receiving post-
-operative chemotherapy and 88% in the control group, HR 
= 1.18 (95% CI 0.43–3.26), p = 0.75. The respective values for 
disease-free survival were 78% and 71%, HR = 0.80 (95% CI 
0.38–1.69), p = 0.56.
The QUASAR study comprised patients with stage II 
of the disease, with both rectal and colon cancers [12, 13]. 
In the rectal cancer patients, an improvement of overall 
survival was observed after 5 years with borderline stati-
stical significance; 78% — in patients with post-operative 
chemotherapy and 74% in the group with observation only, 
HR = 0.77 (95% CI 0.54–1.00), p = 0,05. Yet in the subgroup 
which received pre-operative radiotherapy (n = 203), the 
difference was not significant, HR = 0.44 (95% CI 0.25–1.10).
An overview of randomised studies 
comparing post-operative chemotherapy with 
fluoropyrimidine with and without oxaliplatin
A systematic overview of publications [6] showed 3 ran-
domised studies in a total number of 2675 patients in whom 
post-operative chemotherapy with fluoropyrimidine was 
compared with post-operative chemotherapy with fluoro-
pyrimidine with the addition of oxaliplatin [14–16]. One of 
these studies showed an improvement of overall survival 
rates after the administration of post-operative chemo-
therapy [16]; in the two remaining studies, the difference 
was not statistically significant. Two studies showed some 
improvement after chemotherapy with respect to disease-
-free survival rates [14, 16], whilst in the third one, no effect 
was seen [15]. In two studies, randomisation was performed 
before pre-operative radio-chemotherapy in the patients 
with clinical stage II or III of the disease [14, 15], whereas 
in the third study the randomisation was carried out after 
surgery only in patients with pathological stage III [16]. 
These studies are discussed in detail below. 
In the German CAO/ARO/AIO-04 study, (n = 1265) after 
a median follow-up period of 50 months, the overall survival 
rates after 3 years were 88.7% in those patients receiving oxa-
liplatin and 88.0% in the patients treated only with 5-Fu; HR 
= 0.96 (95% CI 0.72–1.26) [14]. No ‘p’ value was presented, yet 
the 95% confidence interval for the hazard ratio (HR) shows 
that the difference was not statistically significant. The 3-year 
disease-free survival rate amounted to 75.9% and 71.2% re-
spectively; HR 0.79 (95% CI 0.64–0.98), p = 0.03. A limitation 
for the interpretation of the results of this study consisted 
in the difference in the administration of 5-fu between two 
randomised groups: in patients in the group with the addition 
of oxaliplatin, this medication was administered in continuous 
infusion, whilst in the control group — only in a bolus. 
In the PETACC-6 study (n = 1090) after a median follow-
-up period of 68 months, overall survival rates after 5 years 
was 83.1% in patients receiving capecitabin alone and 80.1% 
in patients treated with oxaliplatin with capecitabin; H = 1.17 
(95% CI 0.89–1.54), p = 0.25 [15]. The respective values for 
disease-free survivals were 71.3% and 70.5%, HR = 1.02 (95% 
CI 0.82–1.28) p = 0.84.
In the Korean phase II study (ADORE) with randomisa-
tion of the patients (n = 321) with pathological stage II and 
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III after preoperative radio-chemotherapy with the use of 
5-fu and leucovorin and after tumour resection, the sub-
jects were randomised into two regimens of post-operative 
chemotherapy: FOLFOX and 5-fu in a bolus with leucovorin 
[16]. The median age was only 54. After a median follow-up 
period of 38.2 months, better outcomes were observed in 
patients treated with the addition of oxaliplatin, both in 
3-year disease-free survival rates (71.6% vs 62.9%; HR = 0.66, 
p = 0.047) and in overall survival rates (95.0% and 85.7%; HR 
= 0.46, p = 0.036). Similarly to the German study, the limita-
tion of the interpretation of the results of the Korean study 
was the difference in the administration of 5-fu between the 
two randomised groups: in the group receiving oxaliplatin, 
the medication was administered in continuous infusion, 
whilst in the control group only in a bolus. 
Meta-analyses
Breugom et al. [17] published a meta-analysis with the 
use of individual data of the patients with pathological stage 
II and III [7–11]. The meta-analysis comprised 4 out of 5 of 
the above mentioned studies comparing the results after 
the administration of post-operative chemotherapy with 
the results of the observation without chemotherapy. The 
median observation period was 7 years. No improvements 
in overall survival rates after the administration of chemo-
therapy in comparison with observation was seen; HR = 0.97 
(95% CI 0.81–1.17). No improvement in disease-free survival 
rates was observed either; HR = 0.91 (95% CI 0.77–1.07). In 
the subgroup analysis, only in patients with the rectal cancer 
located 10–15 cm from the edge of the rectum, was there 
some improvement observed in disease-free survival rates 
after chemotherapy; HR = 0.59 (95% CI 0.40–0.85), p = 0.005, 
yet without any improvement of overall survival rates. In 
other subgroups, such as pathological stage II or III, ypN0, 
ypN1 or ypN3, patients after an anterior resection or after 
an abdominoperineal resection (APR), after preoperative 
irradiation 5 × 5 Gy or traditionally fractionated radiotherapy 
or radio-chemotherapy, no improvement after chemother-
apy was seen both with regards to overall survival rates and 
disease-free survivals. 
Another meta-analysis [6], made on the basis of the 
published data concerning all the above listed 5 studies, 
comparing the results after the administration of post-op-
erative chemotherapy with the results after observation 
only without chemotherapy [7–13], also showed a lack of 
any improvement after post-operative chemotherapy with 
respect to overall survivals and disease-free survivals: 0.95 
(95% CI 0.82–1.10), p = 0.49 and 0.92 (95% CI 0.80–1.04), 
p = 0.19. The lack of any improvement after chemotherapy 
was observed both in the subgroups with ypT0–2 stage 
and in the subgroup with metastases to the lymph nodes. 
When the meta-analysis was made separately for the studies 
in which randomisation was carried out after the surgery 
and those in which randomisation was carried out before 
the commencement of preoperative irradiation, it turned 
out that in the first case, better disease-free survival rates 
were observed after the administration of post-operative 
chemotherapy: HR = 0.79 (95% CI 0.62–1.00), p = 0.047, 
yet without any improvement in the overall survival rates. 
In the latter type of randomisation, no positive effect from 
post-operative chemotherapy was observed in the evalua-
tion of overall and disease-free survival rates.
Also a meta-analysis of [6] 3 of the above mentioned 
randomised studies was carried out; in this meta-analysis, 
post-operative chemotherapy with fluoropyrimidine only 
was compared with post-operative chemotherapy with 
fluoropyrimidine plus the addition of oxaliplatin [14–16]. 
The addition of oxaliplatin did not cause any improvement 
of disease-free survival rates; HR = 0.84 (95% CI 0.66–1.06), 
p = 0.15. Overall survival rates were not analysed because 
of the lack of appropriate data at the moment the meta-
-analysis was carried out.
Discussion
The meta-analyses of the randomised studies did not 
show any positive effect of post-operative chemotherapy 
on overall survival rates in patients who previously received 
pre-operative irradiation. The lack of any improvement was 
observed both in the cancer subgroup which responded to 
radiotherapy, i.e., those patients with stage ypT0–2, and in the 
patients with stage III of the disease where the largest effect 
could have been expected. Therefore, no strong evidence 
points to the advisability of post-operative chemotherapy.
It is worth pointing out, however, that an improvement 
of disease-free survival rates (yet without any improvement 
in overall survival rates) was observed in the meta-analysis 
of the studies in which randomisation was carried out after 
surgery [6]. The moment of randomisation overlaps with the 
moment when routinely the decision whether to administer 
chemotherapy or not is taken. In the studies in which ran-
domisation was carried out before surgery, many patients 
did not begin previously planned post-operative chemo-
therapy as a result of post-operative complications, lack of 
further consent of the patient, or disease progression. These 
patients had to be included into the analysis with regards 
to the intention-to-treat principle. However, with regards to 
the poor prognoses of these patients, chances for observing 
treatment benefits decreased. That is why randomisation 
before surgery is suboptimal. The improvement of disease-
-free survival rates (yet with a lack of improvement in overall 
survival rates) after surgery in the randomised studies points 
to the minor influence of post-operative chemotherapy. 
Thus a question arises whether this benefit outweighs the 
toxicity of chemotherapy.
The toxicity of chemotherapy lessens the quality of life 
of patients during treatment [18]. Post-operative chemothe-
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rapy with fluoropyridines leads to acute toxicity consisting 
of diarrhoeas, nausea, vomiting and fatigue as well as pain 
resulting from stomatitis and loss of appetite [18]. In rare 
cases, complications may be life-threatening or might require 
hospitalisation. Toxic deaths occur in about 1% of patients, 
affecting mainly the elderly [19]. The rate of III+ complications 
was observed in 36–40% of patients receiving chemotherapy 
with oxaliplatin [11, 16]. Closure of the colostomy is deferred 
till the moment chemotherapy is completed. The admini-
stration of post-operative chemotherapy is connected with 
the larger costs of treatment. Post-operative chemotherapy 
causes not only acute complications, but also delayed ones. 
The above mentioned EORTC randomised study after 
a median observation period of 4.6 years showed that sta-
tistically more patients reported pain, diarrhoea, weaker 
physical activity and difficulties in everyday activities after 
the administration of post-operative chemotherapy than 
in the control group [20, 21]. Oxaliplatin causes chronic 
neuropathy, the intensification of which can lead to a lower 
quality of life [22].
The controversies concerning the administration of 
post-operative chemotherapy described in this paper po-
int to the fact that a patient should be informed about its 
doubtful efficacy and possible complications. An evaluation 
as to whether the benefits from the use of chemotherapy 
exceed its toxic side-effects is subjective and should be left 
to the patient who must be adequately informed about 
the arguments for and against. It was observed that many 
patients prefer observation without chemotherapy when 
its beneficial effect is only minor [23].
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